Fennec Pharmaceuticals Announces InvestigatorSponsored Study to Be Conducted by University of Arizona Cancer Center

Image for article Fennec Pharmaceuticals Announces InvestigatorSponsored Study to Be Conducted by University of Arizona Cancer Center
News Source : Financial Post

News Summary

  • University of Arizona Cancer Center Initiating Study to Explore Use of PEDMARK® in AYA & Adult Patients with Solid Tumors Receiving Cisplatin.
  • Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX) recently announced the initiation of two other institution-led clinical studies.
  • Additional investigator-initiated studies supporting the use of PedMark® have been submitted to Fennec and are currently under review.
  • PEDmARK is currently approved for pediatric patients one month of age and older with localized, non-metastatic solid tumors.
  • It is also recognized by the National Comprehensive Cancer Network with a 2A recommendation for use in adolescent and young adult patients.
Important Safety Information PEDMARK is contraindicated in patients with history of a severe hypersensitivity to sodium thiosulfate or any of its components.Hypersensitivity reactions occurred in 8 [+5274 chars]

Must read Articles